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OBJECTIVE: The use of the Semmes-Weinstein (SW) monofilament test is recommended as a screening
method for diabetic neuropathy. It offers an important chance to prevent further complications of diabetic
foot. We aimed to develop a prototype Robotic Monofilament Inspector that can be used as a standard
machine for screening of diabetic neuropathy.
METHODS: Development was divided into three parts: computer software, control box, and Robotic
Monofilament Inspector. The examiner conducted the SW test (by hand and by robotic inspector), vibra-
tion perception threshold, and Toronto Clinical Scoring System without knowledge of patient information.
The unpaired t test or Wilcoxon rank-sum test was used to determine the differences between independent
groups in terms of continuous outcomes, while the χ2 test was used to determine categorical outcomes.
Agreement between the various diabetic neuropathy tests was measured using the kappa statistic.
RESULTS: The SW test and vibration perception threshold were more valid tests for neuropathy than
the Toronto test. The robotic test was in excellent agreement with the two former tests and appeared to
be valid (kappa statistic, 0.35–0.81). Another indirect evidence for the validity of the robotic test was the
finding that diabetic patients with foot ulcers had a higher prevalence of neuropathy (77% vs. 38%). This
might indicate that the robotic test was more valid than the manual test.
CONCLUSION: The Robotic Monofilament Inspector could be used as a simple screening machine. This
prototype may be developed further for routine clinical use. [Asian J Surg 2010;33(4):193–8]
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Introduction
Diabetic foot problems are a leading cause of hospitaliza-
tion and amputation in patients with diabetes mellitus.1
The most common cause of nontraumatic lower extrem-
ity amputation reported in many countries is diabetic
foot ulcer.2 Peripheral sensory neuropathy is a major risk
factor that contributes to the development of diabetic
foot ulcer.3 According to a clinical practice guideline for
diabetic foot disorders (2006 revision),4 the Semmes-
Weinstein (SW) monofilament examination has been rec-
ommend for detecting the loss of protective sensation in
diabetic patients.
Diabetic neuropathy comprises a number of different
syndromes ranging from subclinical to clinical.5 It is not
a well-understood complication of diabetes. The loss of
sensory sensation leads to failure to sense and protect
from minor trauma, altered plantar pressure, and foot
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deformities, leading to chronic wounds. The main group
of neurological disturbances in patients with diabetes is
subclinical neuropathy.6
The early identification of neuropathic abnormalities
is crucial because it offers diabetic patients an important
opportunity to prevent further foot complications.7
Several methods are used to detect diabetic neuropathy,
including the nerve conduction test, the vibration sense
test, and validated questionnaires. However, one method
may be valid only for one end of the disease spectrum.
Although there is no agreement on a gold standard for
detecting peripheral neuropathy, an accurate measure-
ment should differ from those with and those without
diabetes.8 The vibration sense test has been used as a gold
standard for detecting diabetic neuropathy.9 A sophisti-
cated test, such as a nerve conduction study, is rarely 
necessary.4
The current level of evidence in the medical literature
focuses primarily on the use of the SW monofilament test
as a simple screening method to detect diabetic neuro-
pathy.10 Several reports have shown the effectiveness of this
test.11−14 Although it is useful, simple, reproducible, and
inexpensive,15 the examination must be performed by a
physician or medical staff member on whom the loss of
time and labour is incurred to patients. Interexaminer vari-
ations can reduce the accuracy of the test result. In this
study, we developed a prototype, Robotic Monofilament
Inspector (RMI) that might be used as a standard machine
for the screening of diabetic neuropathy.
Patients and methods
Conceptual design and hypothesis
This development was divided into three parts: computer
software, control box, and RMI (Figure 1). The physician
could access to the patient’s data either in the clinic or by
remote access. The model of this system was previously
published by our group.16 A brief explanation of this system
follows.
Computer software
The computer software was the program that controlled
the action of all parts and kept the patient demographic
data and test results. This program was commanded by
the doctor or health care professionals. The patient’s
demographic data must be added into the program
before starting the operation (Figure 2).
Control box
The control box was an electronic system that was imple-
mented with an ARM7 microcontroller (Analog Devices
Inc., Norwood, MA, USA). This part received the com-
mand from the computer software and could pass the
command to the monofilament robotics tester. It also
worked as a receiver that got the response from the
answer box (Figure 3).
RMI
The RMI was the machine that controlled the monofila-
ment to specify test sites (patient’s foot). This machine
received the command from the control box and moved the
monofilament with regular force and duration of touch.
There are currently some controversies on the number
of testing sites.12 In this study, the RMI was developed
according to the recommendations of the International
Working Group on diabetic foot.13 The study by McGill
et al14 showed that the combination of the plantar aspects
of the first and fifth metatarsals had a high sensitivity
and specificity for neuropathy. They defined insensate as
when patients did not feel the monofilament at either of
these two sites.
The sites tested in this study were as follows (Figure 4):
the great toe (site 1); the plantar aspect of the first meta-
tarsal (site 2); the plantar aspect of the fifth metatarsal
(site 3). Each site was randomly tested three times. During
the examination, patients were in the sitting position and
gave their response by pushing a button on an “answer
box.” The patients were required to respond before con-
tinuing to the next examination. If the answer was incor-
rect two or more times out of three examinations per site,
the site was considered to be positive. If the answer was
incorrect once or less, the site was considered to be negative.
Design and development
According to the working direction of the monofilament,
a solenoid actuator was applied to the inspector. The
model-testing machine was developed according to the
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Figure 1. Diagram of the three parts, computer software, control
box and the Robotic Monofilament Inspector.
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Figure 2. Graphical user interface in the computer software.
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Figure 3. Control box with ARM7 microcontroller.
3
1
2
Figure 4. Sites to be tested with the monofilament.
tested sites. The first part of the model was tested at the great
toe plantar site. This part had no movement, so the base
was fixed. The second part of the model was tested at the
plantar aspect of the first metatarsal. This part had one
direction of movement on the Y axis. The tested point
could be adjusted manually by moving the slider in and out.
The third part of the model was tested at the plantar aspect
of the fifth metatarsal. This part had two directions of
movements on the X and Y axes. The tested point could
be adjusted manually to fit different feet sizes.
The RMI was tested randomly either before or after
the examination by hand. The testing steps were as 
follows:
(1) The examiner commanded the computer software to
test the patient.
(2) The program sent the action command to the con-
trol box.
(3) The control box processed the command and sent it
to the RMI.
(4) The RMI acted as a command from the control 
box.
(5) The control box waited for the answer from the
patient. The response from the answer box was
passed to the control box and sent to the program.
(6) The program kept the answer.
(7) The step was iterated from Steps 2 to 6 until the total
testing number was met.
(8) The program created the report for consideration of
the result.
Patients
A total of 71 individuals who provided their informed
consent participated in this study. There were 40 partici-
pants who were diagnosed with diabetes and 31 partici-
pants who had normal blood sugar levels. The sex, age,
duration of diabetes, fasting serum glucose, HbA1c, and
presence of diabetic complications were recorded. The
examiner conducted the SW test (by hand and by robotic
inspector), vibration perception threshold (VPT), and
Toronto Clinical Scoring System (CSS) without knowl-
edge of the patients’ lower-extremity neuropathy symp-
toms so as to be blinded from the patients’ perceptions.
The controls were recruited from an outpatient surgical
clinic. They received regular follow-up for at least three years
for other diseases such as hernia, breast mass, and haem-
orrhoid. They had no underlying disease and were healthy.
The SW test
All participants were tested by robotic inspector and by
hand following the practical guidelines on the manage-
ment and prevention of diabetic foot.13 The SW monofil-
ament examination was conducted by hand at three
noncallused sites on each foot (Figure 4): (1) great toe, (2)
plantar aspect of the first metatarsal head, and (3) plan-
tar aspect of the fifth metatarsal head using 5.47/10 g
monofilament. The monofilament was pressed perpendi-
cular to the test site with enough pressure to bend the
monofilament for 1 second. The patients were asked if they
felt anything touching their skin and whether it was on the
left or right foot. The examinations were repeated three
times for each site and included at least one fake examina-
tion. If the answers were incorrect two or more times out of
three examinations per site, the site was considered to be
positive. If the answer was incorrect once or less, the site
was considered to be negative. The examinations were
conducted at all six sites in a random order each time.
Clinical stratification assessment
The neuropathy severity grading was constructed accord-
ing to the simplified Toronto CSS.15 The symptom score
was graded as present = 1 and absent = 0 (numbness or
tingling of the toes and feet). Reflex scores were graded 
as absent = 2, reduced = 1, and normal = 0 for each side.
Sensory test scores was graded as abnormal = 1 and 
normal = 0. The sensory test was performed on the toes.
All symptoms and signs were combined for a total of 
19 points. If the combined scores were between 0 and 5,
the participants were classified as negative for neuro-
pathy. On the other hand, if the combined scores were
more than 5, the participants were classified as positive
for neuropathy.
VPT
The VPT was assessed on both sides of the upper and lower
limb lateral condyles using a C64 quantitative tuning fork
(Takano Manufacturing, Nagoya, Japan) and applied per-
pendicularly.17 Participants were requested to respond
when they first lost the vibratory sensation. The vibration
disappearance threshold was estimated as the intersec-
tion of the two virtual triangles that moved on a scale
from 0 to 8. An average threshold below 4 was considered
to be abnormal.
Statistical analyses
Continuous data were summarized as mean (SD) or
median (range) as appropriate. Categorical data were sum-
marized as counts and percentage. The unpaired t test or
Wilcoxon rank-sum test was used to determine the differ-
ences between independent groups in terms of continuous
outcomes, while the χ2 test was used to determine categori-
cal outcomes. Agreement between the various diabetic neu-
ropathy tests was measured using the kappa statistic.
Statistical significance was defined as a p-value of 0.05 or
less. Stata Statistical software version 9 (StataCorp, College
Station, TX, USA) was used for all statistical analyses.
Results
The participants included 40 diabetic patients, 13 (33%)
of whom had foot ulcers, and 31 controls with normal
blood sugar and no foot ulcers. A total of 78% of the dia-
betic group had a clinical neuropathy score of more than
five. In the nondiabetic group, there were no cases of
symptomatic neuropathy and the clinical score of neu-
ropathy was less than five. The clinical characteristics of
the participants are presented in Table 1.
According to the various neuropathy tests, the preva-
lence of neuropathy in the two groups are presented in
Table 2. The highest prevalence of diabetic neuropathy
was found when using the clinical score. The agreement
between the robotic test, the manual SW test, and other
neuropathy tests in terms of the kappa statistic is given in
Table 3. The clinical score had the lowest agreement. The
prevalence of neuropathy in diabetic patients with or
without foot ulcers according to various neuropathy tests
are given in Table 4. The lowest prevalence of neuropathy
in diabetic foot ulcer was found in the manual SW test.
Discussion
The principle behind the use of the SW monofilament
test is calibration to buckling when a force is exerted. 
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If the patient cannot feel the pressure, the foot is consid-
ered to be insensate.18 Although conceptually simple, there
is no universally accepted guideline on how the monofila-
ment is to be used or how the results are interpreted.19
Variations in the use of the monofilament lead to signifi-
cant differences in the diagnosis and prevalence of diabetic
neuropathy, which affect the workload requirements and
educational and treatment programs of patients.20
Because there is no accepted gold standard method of
diagnosing diabetic neuropathy, a new method of testing
must be compared with currently established methods. In
the present study, the robotic monofilament test was
shown to agree well with the established SW monofila-
ment method (Table 3). Both methods agreed well with
the vibration perception test, but not so well with the
Toronto CSS. The vibration perception test also did not
agree well with the Toronto CSS. The latter method
yielded a higher prevalence of neuropathy, even in the
control (nondiabetic) group, in which the occurrence 
of neuropathy was not expected (Table 2). The Toronto
CSS was probably oversensitive in detecting neuropathy
because the multi-item questionnaire, with items that are
difficult to reliably elicit, might be prone to false positive
findings.
Given that the SW test and VPT might be more valid
tests for neuropathy than the Toronto CSS, the present
finding that the robotic test was in excellent agreement
with the two former tests would seem to indicate that the
robotic test is also valid. Another indirect evidence for the
validity of the robotic test was that, according to the test,
diabetic patients with foot ulcers had a higher prevalence
of neuropathy, as might be expected (Table 4). In contrast,
the manual SW test indicated that neuropathy was more
prevalent in diabetics with no foot ulcers (Table 4). This
might indicate that the robotic test was even more valid
than the SW test.
One limitation of the present study was that the re-
liability of the robotic test was not systematically deter-
mined. Preliminary experience with the robotic test
seemed to indicate that the test was highly reproducible,
as designed, yielding identical results almost every time.
The current model of the robotic monofilament test is
simple to implement, but it requires some training to
achieve reliable results. Future modifications may further
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Table 1. Clinical characteristics of participants
Characteristic DM group (n= 40) Non-DM group (n= 31) p
Age (yr): mean (SD) 62.8 (9.7) 59.3 (7.7) 0.112
Gender (male): n (%) 20 (50%) 7 (23%) 0.018
FBS (mg, %): median (range) 130 (85–285) 83 (72–108) < 0.001
Foot ulcer (yes): n (%) 13 (33%) 0 NA
HbA1c: mean (SD) 7.56 (1.56) – NA
DM = diabetes melliteus; FBS = fasting blood sugar; NA = not applicable.
Table 2. Prevalence of neuropathy in the participants according to various tests
Neuropathy test DM group (n= 40) Non-DM group (n= 31) p
Robotic monofilament test (positive) 26 (65%) 2 (6%) < 0.001
Manual SW test (positive) 21 (53%) 1 (3%) < 0.001
VPT (< 4) 25 (63%) 3 (10%) < 0.001
Toronto CSS (> 5) 31 (78%) 4 (13%) < 0.001
SW = Semmes-Weinstein monofilament examination; VPT = vibration perception threshold; CSS = clinical scoring system.
Table 3. Agreement between pairs of neuropathy tests
Pair of neuropathy tests Kappa statistic (SE)
Robotic and SW 0.816 (0.117)
Robotic and VPT 0.941 (0.119)
Robotic and Toronto CSS 0.350 (0.116)
SW and VPT 0.755 (0.117)
SW and Toronto CSS 0.292 (0.110)
VPT and Toronto CSS 0.294 (0.116)
SE = standard error; SW = Semmes-Weinstein monofilament exami-
nation; VPT = vibration perception threshold; CSS = clinical scoring
system.
simplify the setup and increase its acceptability among
clinicians. A standardized approach should make the
monofilament test less prone to measurement bias.
The result of this study demonstrated that an RMI
could be used as a simple screening machine. The validity
of this novel test should be comparable to the manual SW
monofilament test, and perhaps more so. This prototype
may be developed further for routine clinical use.
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Table 4. Prevalence of neuropathy in diabetic patients with or without foot ulcers
Test With foot ulcer (n= 13) No foot ulcer (n= 27) p
Robotic 10 (77%) 16 (59%) 0.273
SW 5 (38%) 16 (59%) 0.217
VPT 9 (69%) 16 (59%) 0.542
Toronto CSS 7 (54%) 24 (89%) 0.013
SW = Semmes-Weinstein monofilament examination; VPT = vibration perception threshold; CSS = clinical scoring system.
